Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cycloserine.

Literature DB >> 18486041

Cycloserine.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2008 PMID： 18486041 DOI： 10.1016/S1472-9792(08)70007-6

Source DB: PubMed Journal: Tuberculosis (Edinb) ISSN： 1472-9792 Impact factor: 3.131

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors: Xia Yu; Xiling Zeng; Wenhui Shi; Yanjie Hu; Wenjuan Nie; Naihui Chu; Hairong Huang
Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191

Review 2. Advances in the development of new tuberculosis drugs and treatment regimens.

Authors: Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal: Nat Rev Drug Discov Date: 2013-05 Impact factor: 84.694

3. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405

10. A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains.

Authors: Jeffrey M Chen; Swapna Uplekar; Stephen V Gordon; Stewart T Cole
Journal: PLoS One Date: 2012-08-17 Impact factor: 3.240

Cycloserine.

1. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.

Review 2. Advances in the development of new tuberculosis drugs and treatment regimens.

3. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

4. Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.

Review 5. Safety and tolerability profile of second-line anti-tuberculosis medications.

6. PepD participates in the mycobacterial stress response mediated through MprAB and SigE.

Review 7. The Role of Serine Racemase in the Pathophysiology of Brain Disorders.

8. Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Review 9. Natural cinnamic acids, synthetic derivatives and hybrids with antimicrobial activity.

10. A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains.